Posttranslational regulation of Akt in human cancer
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Akt regulates critical cellular processes including cell survival and proliferation, glucose metabolism, cell migration, cancer progression and metastasis through phosphorylation of a variety of downstream targets. The Akt pathway is one of the most prevalently hyperactivated signaling pathways in human cancer, thus, research deciphering molecular mechanisms which underlie the aberrant Akt activation has received enormous attention. The PI3K-dependent Akt serine/threonine phosphorylation by PDK1 and mTORC2 has long been thought to be the primary mechanism accounting for Akt activation. However, this regulation alone does not sufficiently explain how Akt hyperactivation can occur in tumors with normal levels of PI3K/PTEN activity. Mounting evidence demonstrates that aberrant Akt activation can be attributed to other posttranslational modifications, which include tyrosine phosphorylation, O-GlcNAcylation, as well as lysine modifications: ubiquitination, SUMOylation and acetylation. Among them, K63-linked ubiquitination has been shown to be a critical step for Akt signal activation by facilitating its membrane recruitment. Deficiency of E3 ligases responsible for growth factor-induced Akt activation leads to tumor suppression. Therefore, a comprehensive understanding of posttranslational modifications in Akt regulation will offer novel strategies for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · cited 2×
“Extensive studies have established that growth factors, hormones and cytokines stimulate Akt activation through serial phosphorylation events [24,25].”
BackgroundInhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244 · cited 1×
“Akt phosphorylation of GSK3β, a protein kinase known to downregulate protein substrates for cell survival and proliferation, causes cells to reacquire survival features [7].”
BackgroundNegative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
The DNA Damage Response: Ten Years After
Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705 · cited 1×
“Ubiquitination, just like phosphorylation, is a dynamic modification engaged in diverse cellular processes including cell growth and proliferation, apoptosis, DNA damage response, inflammation, cancer and neurodegenerative diseases [50-55].”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Gao, T., Furnari, F., & Newton, A. C. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.008 · Cited by 906 · cited 1×
“In addition to PTEN, two phosphatases, protein phosphatase 2A (PP2A) and PH domain and leucine rich repeat protein phosphatase (PHLPP), were found to dephosphorylate Akt at Thr308 and Ser473, respectively, thereby antagonizing Akt activation [36-38].”
BackgroundSerra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787 · cited 1×
“eral preclinical models [78-81].”
Research works printed but not linked: 83
- Bellacosa A, Testa JR, Staal SP, Tsichlis PN: A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991, 254: 274-277. 10.1126/science.1833819 · DOI · Paper page
- Bellacosa A, Franke TF, Gonzalez-Portal ME, Datta K, Taguchi T, Gardner J, Cheng JQ, Testa JR, Tsichlis PN: Structure, expression and chromosomal mapping of c-akt: relationship to v-akt and its implications. Oncogene. 1993, 8: 745-754.
- Coffer PJ, Woodgett JR: Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem. 1991, 201: 475-481. 10.1111/j.1432-1033.1991.tb16305.x · DOI · Paper page
- Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA: Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A. 1991, 88: 4171-4175. 10.1073/pnas.88.10.4171 · DOI · Paper page
- Eijkelenboom A, Burgering BM: FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol. 2013, 14: 83-97. 10.1038/nrm3507 · DOI · Paper page
- Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91: 231-241. 10.1016/S0092-8674(00)80405-5 · DOI · Paper page
- Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999, 401: 82-85. 10.1038/43466 · DOI · Paper page
- Gao D, Inuzuka H, Tseng A, Chin RY, Toker A, Wei W: Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol. 2009, 11: 397-408. 10.1038/ncb1847 · DOI · Paper page
- Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer S, Tempst P, Pandolfi PP: Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 2009, 11: 420-432. 10.1038/ncb1849 · DOI · Paper page
- Chan CH, Lee SW, Wang J, Lin HK: Regulation of Skp2 expression and activity and its role in cancer progression. The Scientific World JOURNAL. 2010, 10: 1001-1015. · DOI · Paper page
- Chan CH, Gao Y, Moten A, Lin HK: Novel ARF/p53-independent senescence pathways in cancer repression. J Mol Med. 2011, 89: 857-867. 10.1007/s00109-011-0766-y · DOI
- Ecker K, Hengst L: Skp2: caught in the Akt. Nat Cell Biol. 2009, 11: 377-379. 10.1038/ncb0409-377 · DOI
- Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004, 304: 554. 10.1126/science.1096502 · DOI · Paper page
- Cully M, You H, Levine AJ, Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006, 6: 184-192. 10.1038/nrc1819 · DOI · Paper page
- Fruman DA, Rommel C: PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014, 13: 140-156. 10.1038/nrd4204 · DOI · Paper page
- Gonzalez E, McGraw TE: The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle. 2009, 8: 2502-2508. 10.4161/cc.8.16.9335 · DOI · Paper page
- Gonzalez E, McGraw TE: Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling. Proc Natl Acad Sci U S A. 2009, 106: 7004-7009. 10.1073/pnas.0901933106 · DOI · Paper page
- Brazil DP, Park J, Hemmings BA: PKB binding proteins. Getting in on the Akt. Cell. 2002, 111: 293-303. 10.1016/S0092-8674(02)01083-8 · DOI · Paper page
- Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996, 15: 6541-6551. · DOI · Paper page
- Bozulic L, Surucu B, Hynx D, Hemmings BA: PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell. 2008, 30: 203-213. 10.1016/j.molcel.2008.02.024 · DOI · Paper page
- Feng J, Park J, Cron P, Hess D, Hemmings BA: Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem. 2004, 279: 41189-41196. 10.1074/jbc.M406731200 · DOI · Paper page
- Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, Dedhar S: Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A. 2000, 97: 3207-3212. 10.1073/pnas.97.7.3207 · DOI · Paper page
- Fayard E, Tintignac LA, Baudry A, Hemmings BA: Protein kinase B/Akt at a glance. J Cell Sci. 2005, 118: 5675-5678. 10.1242/jcs.02724 · DOI · Paper page
- Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, Tsou P, Gan W, Papa A, Kim BM, Wan L, Singh A, Zhai B, Yuan M, Wang Z, Gygi SP, Lee TH, Lu KP, Toker A, Pandolfi PP, Asara JM, Kirschner MW, Sicinski P, Cantley L, Wei W: Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature. 2014, 508: 541-545. 10.1038/nature13079 · DOI · Paper page
- Gao Y, Moten A, Lin HK: Akt: a new activation mechanism. Cell Res. 2014, 24: 785-786. 10.1038/cr.2014.57 · DOI
- Salmena L, Carracedo A, Pandolfi PP: Tenets of PTEN tumor suppression. Cell. 2008, 133: 403-414. 10.1016/j.cell.2008.04.013 · DOI · Paper page
- Arroyo JD, Hahn WC: Involvement of PP2A in viral and cellular transformation. Oncogene. 2005, 24: 7746-7755. 10.1038/sj.onc.1209038 · DOI · Paper page
- Millward TA, Zolnierowicz S, Hemmings BA: Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci. 1999, 24: 186-191. 10.1016/S0968-0004(99)01375-4 · DOI · Paper page
- Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP: Identification of a tumour suppressor network opposing nuclear Akt function. Nature. 2006, 441: 523-527. 10.1038/nature04809 · DOI · Paper page
- Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, Caron MG: A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell. 2008, 132: 125-136. 10.1016/j.cell.2007.11.041 · DOI · Paper page
- Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG: An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005, 122: 261-273. 10.1016/j.cell.2005.05.012 · DOI · Paper page
- Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, Chen H, Qiu Y: Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem. 2001, 276: 31858-31862. 10.1074/jbc.C100271200 · DOI · Paper page
- Zheng Y, Peng M, Wang Z, Asara JM, Tyner AL: Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol. 2010, 30: 4280-4292. 10.1128/MCB.00024-10 · doi:10.1128/mcb.00024-10
- Luan B, Zhao J, Wu H, Duan B, Shu G, Wang X, Li D, Jia W, Kang J, Pei G: Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature. 2009, 457: 1146-1149. 10.1038/nature07617 · DOI · Paper page
- Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schonbrunn E, Sebti SM, Earp HS, Mahajan NP: Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One. 2010, 5: e9646. 10.1371/journal.pone.0009646 · DOI · Paper page
- Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007, 448: 439-444. 10.1038/nature05933 · DOI · Paper page
- Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68: 6084-6091. 10.1158/0008-5472.CAN-07-6854 · DOI · Paper page
- Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, Moses T, Carpten JD: PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol. 2008, 140: 344-347. 10.1111/j.1365-2141.2007.06920.x · DOI
- Chen ZJ, Sun LJ: Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell. 2009, 33: 275-286. 10.1016/j.molcel.2009.01.014 · DOI · Paper page
- Bhoj VG, Chen ZJ: Ubiquitylation in innate and adaptive immunity. Nature. 2009, 458: 430-437. 10.1038/nature07959 · DOI · Paper page
- Corn JE, Vucic D: Ubiquitin in inflammation: the right linkage makes all the difference. Nat Struct Mol Biol. 2014, 21: 297-300. 10.1038/nsmb.2808 · DOI
- Hoeller D, Dikic I: Targeting the ubiquitin system in cancer therapy. Nature. 2009, 458: 438-444. 10.1038/nature07960 · DOI · Paper page
- Segref A, Hoppe T: Think locally: control of ubiquitin-dependent protein degradation in neurons. EMBO Rep. 2009, 10: 44-50. 10.1038/embor.2008.229 · DOI · Paper page
- Adhikari A, Chen ZJ: Diversity of polyubiquitin chains. Dev Cell. 2009, 16: 485-486. 10.1016/j.devcel.2009.04.001 · DOI
- Yang WL, Wu CY, Wu J, Lin HK: Regulation of Akt signaling activation by ubiquitination. Cell Cycle. 2010, 9: 487-497.
- Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N: Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 2003, 63: 2139-2144.
- Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, Powell SN, Yang Q: Negative regulation of AKT activation by BRCA1. Cancer Res. 2008, 68: 10040-10044. 10.1158/0008-5472.CAN-08-3009 · DOI
- Suizu F, Hiramuki Y, Okumura F, Matsuda M, Okumura AJ, Hirata N, Narita M, Kohno T, Yokota J, Bohgaki M, Obuse C, Hatakeyama S, Obata T, Noguchi M: The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. Dev Cell. 2009, 17: 800-810. 10.1016/j.devcel.2009.09.007 · DOI
- Bae S, Kim SY, Jung JH, Yoon Y, Cha HJ, Lee H, Kim K, Kim J, An IS, Kim J, Um HD, Park IC, Lee SJ, Nam SY, Jin YW, Lee JH, An S: Akt is negatively regulated by the MULAN E3 ligase. Cell Res. 2012, 22: 873-885. 10.1038/cr.2012.38 · DOI
- Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, Lin HK: The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009, 325: 1134-1138. 10.1126/science.1175065 · DOI · Paper page
- Fan CD, Lum MA, Xu C, Black JD, Wang X: Ubiquitin-dependent regulation of phospho-AKT dynamics by the ubiquitin E3 ligase, NEDD4-1, in the insulin-like growth factor-1 response. J Biol Chem. 2013, 288: 1674-1684. 10.1074/jbc.M112.416339 · DOI · Paper page
- Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, Nakayama KI, Lin HK: The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012, 149: 1098-1111. 10.1016/j.cell.2012.02.065 · DOI · Paper page
- Li W, Peng C, Lee MH, Lim D, Zhu F, Fu Y, Yang G, Sheng Y, Xiao L, Dong X, Ma W, Bode AM, Cao Y, Dong Z: TRAF4 is a critical molecule for Akt activation in lung cancer. Cancer Res. 2013, 73: 6938-6950. 10.1158/0008-5472.CAN-13-0913 · DOI
- Lim JH, Jono H, Komatsu K, Woo CH, Lee J, Miyata M, Matsuno T, Xu X, Huang Y, Zhang W, Park SH, Kim YI, Choi YD, Shen H, Heo KS, Xu H, Bourne P, Koga T, Xu H, Yan C, Wang B, Chen LF, Feng XH, Li JD: CYLD negatively regulates transforming growth factor-beta-signalling via deubiquitinating Akt. Nat Commun. 2012, 3: 771. · DOI · Paper page
- Yang WL, Jin G, Li CF, Jeong YS, Moten A, Xu D, Feng Z, Chen W, Cai Z, Darnay B, Gu W, Lin HK: Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling. Sci Signal. 2013, 6: ra3.
- Li R, Wei J, Jiang C, Liu D, Deng L, Zhang K, Wang P: Akt SUMOylation regulates cell proliferation and tumorigenesis. Cancer Res. 2013, 73: 5742-5753. 10.1158/0008-5472.CAN-13-0538 · DOI · Paper page
- Risso G, Pelisch F, Pozzi B, Mammi P, Blaustein M, Colman-Lerner A, Srebrow A: Modification of Akt by SUMO conjugation regulates alternative splicing and cell cycle. Cell Cycle. 2013, 12: 3165-3174. · DOI
- Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, Raghuraman H, Cunningham JM, Gupta M, Gupta MP: The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal. 2011, 4: ra46. · DOI · Paper page
- Vosseller K, Wells L, Lane MD, Hart GW: Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A. 2002, 99: 5313-5318. 10.1073/pnas.072072399 · DOI · Paper page
- Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV, Kudlow JE, Michell RH, Olefsky JM, Field SJ, Evans RM: Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature. 2008, 451: 964-969. 10.1038/nature06668 · DOI · Paper page
- Soesanto YA, Luo B, Jones D, Taylor R, Gabrielsen JS, Parker G, McClain DA: Regulation of Akt signaling by O-GlcNAc in euglycemia. Am J Physiol Endocrinol Metab. 2008, 295: E974-E980. 10.1152/ajpendo.90366.2008 · DOI
- Wang S, Huang X, Sun D, Xin X, Pan Q, Peng S, Liang Z, Luo C, Yang Y, Jiang H, Huang M, Chai W, Ding J, Geng M: Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates Akt signaling. PLoS One. 2012, 7: e37427. 10.1371/journal.pone.0037427 · DOI
- Shi J, Wu S, Dai CL, Li Y, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX: Diverse regulation of AKT and GSK-3beta by O-GlcNAcylation in various types of cells. FEBS Lett. 2012, 586: 2443-2450. 10.1016/j.febslet.2012.05.063 · DOI
- Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005, 4: 988-1004. 10.1038/nrd1902 · DOI · Paper page
- Liu P, Cheng H, Roberts TM, Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009, 8: 627-644. 10.1038/nrd2926 · DOI · Paper page
- Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006, 9: 341-349. 10.1016/j.ccr.2006.03.029 · DOI · Paper page
- Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP: Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res. 2009, 15: 4147-4156. 10.1158/1078-0432.CCR-08-2814 · DOI · Paper page
- Ihle NT, Lemos R, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G: Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009, 69: 143-150. 10.1158/0008-5472.CAN-07-6656 · DOI · Paper page
- Porta C, Paglino C, Mosca A: Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014, 4: 64. · DOI · Paper page
- Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011, 19: 575-586. 10.1016/j.ccr.2011.04.008 · DOI · Paper page
- Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG, Wu H: Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011, 19: 792-804. 10.1016/j.ccr.2011.05.006 · DOI · Paper page
- Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J: PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011, 30: 2547-2557. 10.1038/onc.2010.626 · DOI · Paper page
- Lin A, Piao HL, Zhuang L, Sarbassov dos D, Ma L, Gan B: FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res. 2014, 74: 1682-1693. 10.1158/0008-5472.CAN-13-1729 · DOI · Paper page
- Fensterle J, Aicher B, Seipelt I, Teifel M, Engel J: Current view on the mechanism of action of perifosine in cancer. Anti Cancer Agents Med Chem. 2014, 14: 629-635. 10.2174/1871520614666140309225912. 10.2174/1871520614666140309225912 · doi:10.2174/1871520614666140309225912
- Meuillet EJ, Ihle N, Baker AF, Gard JM, Stamper C, Williams R, Coon A, Mahadevan D, George BL, Kirkpatrick L, Powis G: In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res. 2004, 14: 513-527. · DOI
- Wang Z, Liu P, Inuzuka H, Wei W: Roles of F-box proteins in cancer. Nat Rev Cancer. 2014, 14: 233-247. 10.1038/nrc3700 · DOI · Paper page
- Chan CH, Morrow JK, Zhang S, Lin HK: Skp2: a dream target in the coming age of cancer therapy. Cell Cycle. 2014, 13: 679-680. 10.4161/cc.27853 · DOI
- Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, Kadowaki T, Hay N: Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001, 15: 2203-2208. 10.1101/gad.913901 · DOI · Paper page
- Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, Watanabe T, Michaelis T, Frahm J, Hemmings BA: Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development. 2005, 132: 2943-2954. 10.1242/dev.01864 · DOI · Paper page
- Stambolic V, Woodgett JR: Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends Cell Biol. 2006, 16: 461-466. 10.1016/j.tcb.2006.07.001 · DOI · Paper page
- Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, Natesan S, Brugge JS: Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol. 2005, 171: 1023-1034. 10.1083/jcb.200505087 · DOI · Paper page
- Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A: Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell. 2005, 20: 539-550. 10.1016/j.molcel.2005.10.033 · DOI · Paper page
- Maroulakou IG, Oemler W, Naber SP, Tsichlis PN: Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res. 2007, 67: 167-177. 10.1158/0008-5472.CAN-06-3782 · DOI · Paper page
Cited by
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“199 204 Moreover, Akt can activate mTORC1, further promoting cell growth and protein synthesis.”
BackgroundAkt in cancer: Mediator and more
Revathidevi, S., & Munirajan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.002 · Cited by 691
The relation between PI3K/AKT signalling pathway and cancer
Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S., & Baradaran, B. (2019) · Gene · doi:10.1016/j.gene.2019.02.076 · Cited by 651
Metadata
- Authors
- Chan, C.-H., Jo, U., Kohrman, A., Rezaeian, A. H., Chou, P.-C., Logothetis, C., & Lin, H.-K.
- Venue
- Cell & Bioscience
- Published
- 2014-10-01
- Volume
- 4
- Issue
- 1
- Pages
- 59-59
- ISSN
- 2045-3701 (ISSN-L)
- OpenAlex
- W2097733751
- Cited by
- 140
- References
- 15
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Posttranslational regulation of Akt in human cancer. https://app.cochat.ai/papers/10.1186/2045-3701-4-59
- The paper
- Chan, C.-H., Jo, U., Kohrman, A., Rezaeian, A. H., Chou, P.-C., Logothetis, C., & Lin, H.-K. (2014). Posttranslational regulation of Akt in human cancer. Cell & Bioscience. https://doi.org/10.1186/2045-3701-4-59
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.